©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Phosphatidylinositol 3-Kinase Is an Early Intermediate in the G-mediated Mitogen-activated Protein Kinase Signaling Pathway (*)

(Received for publication, February 21, 1996; and in revised form, April 5, 1996)

Brian E. Hawes (§) Louis M. Luttrell (¶) Tim van Biesen (**) Robert J. Lefkowitz (§§)

From the Howard Hughes Medical Institute, Duke University Medical Center, Durham, North Carolina 27710

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The beta-subunit of G(i) mediates mitogen-activated protein (MAP) kinase activation through a signaling pathway involving Shc tyrosine phosphorylation, subsequent formation of a multiprotein complex including Shc, Grb2, and Sos, and sequential activation of Ras, Raf, and MEK. The mechanism by which Gbeta mediates tyrosine phosphorylation of Shc, however, is unclear. This study assesses the role of phosphatidylinositol 3-kinase (PI-3K) in Gbeta-mediated MAP kinase activation. We show that G(i)-coupled receptor- and Gbeta-stimulated MAP kinase activation is attenuated by the PI-3K inhibitors wortmannin and LY294002 or by overexpression of a dominant negative mutant of the p85 subunit of PI-3K. Wortmannin and LY294002 also inhibit G(i)-coupled receptor-stimulated Ras activation. The PI-3K inhibitors do not affect MAP kinase activation stimulated by overexpression of Sos, a constitutively active mutant of Ras, or a constitutively active mutant of MEK. These results demonstrate that PI-3K activity is required in the Gbeta-mediated MAP kinase signaling pathway at a point upstream of Sos and Ras activation.


INTRODUCTION

The cellular signaling pathways leading to receptor-tyrosine kinase- (RTK) (^1)and G protein-coupled receptor- (GPCR) stimulated mitogen-activated protein (MAP) kinase activation have recently been the subject of intense investigation (1, 2, 3, 4, 5, 6) . The signaling pathway of RTK-mediated MAP kinase activation is the most clearly understood. Epidermal growth factor (EGF) stimulation, for example, produces activation and autophosphorylation of the EGF receptor leading to the formation of a multiprotein complex containing the phosphorylated receptor, the phosphoprotein Shc, the adaptor protein Grb2, and the Ras-GTP exchange factor Sos(7, 8, 9) . Sos catalyzes exchange of GTP for GDP on the small guanine nucleotide-binding protein, Ras, thereby stimulating Ras activation(10) . Ras-GTP activates a kinase cascade involving Raf, MEK, and MAP kinase(11, 12, 13) . Activated MAP kinases phosphorylate and activate transcription factors involved in cell growth and proliferation(1) .

The signaling pathways utilized by G(i)-, G(s)-, G(o)-, and G(q)-coupled receptors to stimulate MAP kinase activation have also been assessed and compared(14, 15, 16, 17, 18) . In many cell types, G(i)-coupled receptors mediate MAP kinase activation via the beta-dependent activation of Ras (14, 15, 16) . Several of the intermediate steps in the Gbeta-stimulated MAP kinase pathway are identical with the RTK-stimulated signaling cascade including Shc phosphorylation, Shc/Grb2 association, and Sos activation(19) . Inhibitors of Src family tyrosine kinase activity abrogate G(i)-coupled receptor- and Gbeta-mediated Shc phosphorylation and MAP kinase activation in COS-7 cells (3, 17, 20, 21) suggesting that a Src family tyrosine kinase may be involved in the Gbeta-mediated MAP kinase activation pathway at a point upstream of Ras activation. The mechanism by which Gbeta subunits mediate activation of a tyrosine kinase resulting in increased Shc phosphorylation, however, is unclear.

Recent studies have suggested that phosphatidylinositol 3-kinase (PI-3K) activity may be involved in both RTK- and GPCR-mediated mitogenic signaling(22, 23, 24, 25, 26, 27, 28, 29) . However, the role of PI-3K in mitogenic signaling pathways has not been clearly elucidated. In this study, we assess the role of PI-3K in the Gbeta-mediated MAP kinase signaling pathway using two inhibitors of PI-3K activity, wortmannin (30) and LY294002, and a dominant negative mutant of the p85 subunit of PI-3K (Deltap85).


EXPERIMENTAL PROCEDURES

Materials

COS-7 and CHO cells were from the American Type Culture Collection. Culture media and LipofectAMINE were from Life Technologies, Inc. Fetal bovine serum (FBS) and gentamicin were from Life Technologies Inc. LY294002 was from Bio-Mol. Monoclonal antibody 12CA5 was from Boehringer Mannheim, and anti-ERK2 polyclonal antibody was from Santa Cruz Biotechnology. Protein A-agarose was from Pharmacia Biotech Inc. [-P]ATP was from DuPont NEN. Myelin basic protein (MBP) and wortmannin were from Sigma. UK-14304 was from Pfizer. The cDNAs for the human alpha2-C10 AR and betaARK1 were cloned in our laboratory(31) ; cDNAs encoding Gbeta1 and G2 were provided by M. Simon; cDNA encoding hemagglutinin (HA)-tagged p44 (ERK1) was from J. Pouysségur; cDNA encoding Deltap85 was from M. Sakaue. Constitutively active MEK was from R. Erickson.

Cell Culture and Transfection

COS-7 and CHO-K1 cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) and F-12 medium, respectively, supplemented with 10% FBS and 50 µg/ml gentamicin. Cells were transiently transfected using LipofectAMINE as described previously(17) . Assays were performed 48 h after transfection. In MAP kinase activation assays, transfected cells were serum-starved in DMEM containing 0.5% serum for 16 to 20 h prior to simulation.

Measurement of MAP Kinase Activity

Activity of epitope-tagged p44 (HA-ERK1), or endogenous ERK2, was determined following immunoprecipitation, using MBP as substrate (32) with modifications as described(33) . Quantitation of labeled MBP was performed using a Molecular Dynamics PhosphorImager.

Measurement of Inositol Phosphate Production

Transfected cells were labeled overnight with [^3H]inositol (1-2 µCi/ml) in DMEM containing 10% FBS, washed once with phosphate-buffered saline, and incubated in phosphate-buffered saline containing 1.0 mM CaCl(2), 10 mM LiCl, and the indicated agonist for 45 min. Cells were lysed in 0.4 M perchloric acid (1 ml/well), and 0.8-ml aliquots were neutralized with 0.4 ml of 0.72 M KOH, 0.6 M KHCO(3). Total inositol phosphate accumulation was quantitated using Dowex anion exchange chromatography as described previously(34) .

Measurement of Ras Activation

Ras activation was determined as described previously(14, 35) . Ras-bound GDP and GTP were quantitated using a Molecular Dynamic PhosphorImager. Ras activation is expressed as the amount of GTP bound to Ras as a percent of total guanine nucleotide bound to Ras.


RESULTS AND DISCUSSION

The beta subunit of G(i) mediates Ras-dependent MAP kinase activation produced by stimulation of both the lysophosphatidic acid (LPA) receptor and alpha adrenergic receptor (alpha(2)AR)(14) . In order to determine whether PI-3K activity is required in the Gbeta-mediated mitogenic signaling pathway, we assessed the effect of two chemical PI-3K inhibitors (wortmannin and LY294002) and the effect of overexpression of a dominant negative mutant of the p85 subunit of PI-3K (Deltap85) on G(i)-coupled receptor- and Gbeta-mediated MAP kinase activation. As shown in Fig. 1A, pretreatment of COS-7 cells with wortmannin or LY294002 markedly inhibits MAP kinase activation produced by stimulation of the endogenously expressed LPA receptor. This inhibition of the LPA signal was also detectable at the level of endogenous MAP kinase (ERK2) (Fig. 1A, right panel). Similar inhibition by wortmannin and LY294002 is observed on MAP kinase activation provoked by stimulation of transiently overexpressed alpha(2)AR and direct transfection of Gbeta (Fig. 1B). Wortmannin and Ly294002 pretreatment also inhibit G(i)PCR- and Gbeta-mediated MAP kinase activation in CHO-K1 cells (data not shown). In contrast, wortmannin and LY294002 have a lesser effect on MAP kinase activation stimulated by phorbol 12-myristate 13-acetate (PMA), or epidermal growth factor (EGF) (Fig. 1B). The inhibition by wortmannin and LY294002 is limited to the MAP kinase signaling pathway, in that the PI-3K inhibitors do not affect alpha(2)AR- or Gbeta-mediated phosphoinositide hydrolysis (Fig. 1C). Both wortmannin and LY294002 inhibit LPA and Gbeta-stimulated MAP kinase activation in a concentration-dependent manner (Fig. 1, D and E), with IC values of 100 nM and 1.0 µM for wortmannin and LY294002, respectively.


Figure 1: Effect of PI-3K inhibitors on G(i)-coupled receptor- and Gbeta-mediated MAP kinase activation and IP production. COS-7 cells were cotransfected with plasmid DNA encoding p44 (0.1 µg/well) and either pRK5 alone (2.0 µg/well), Gbeta1 and 2 (1.0 µg each/well), or alpha(2)AR (0.2 µg/well). Cells in A (right panel) were untransfected, stimulated with 10 µM LPA, and assayed for endogenous ERK2 activity. Cells were pretreated for 15 min with wortmannin (1.0 µM), LY294002 (20 µM), or vehicle (A, B, and C) or with the indicated concentration of wortmannin (D) or LY294002 (E). Cells were stimulated with LPA (10 µM), the alpha(2)AR agonist UK-14304 (10 µM), or PMA (1.0 µM) unless indicated for 5 min (A, B, D, and E), and MAP kinase activation was determined for 45 min (C) and IP production was measured. In A, B, and C, data are expressed as fold stimulation where basal is defined as 1.0. In D and E, data are expressed as a percent of the stimulation produced by LPA or Gbeta in the absence of wortmannin or LY294002. Values in A are the mean ± S.D. from one representative experiment. All other values are the mean ± S.E. from at least three separate experiments. The absence of error bars indicates the S.D. or S.E. is smaller than the size of the symbol.



A recent study (36) reported that expression of a dominant negative mutant of p85alpha (Deltap85), which lacks the p110 binding site, inhibits insulin-stimulated PI-3K activity and PIP(3) production. The effect of Deltap85 expression on G(i)-coupled receptor- and Gbeta-stimulated MAP kinase activation is shown in Fig. 2. Expression of Deltap85 inhibits LPA-, alpha(2)AR-, and Gbeta-stimulated MAP kinase activation without affecting MAP kinase activation stimulated by PMA. Thus, expression of a dominant negative mutant of PI-3K produces effects similar to wortmannin and LY294002. These results strongly suggest that PI-3K activity is an essential component of the Gbeta-mediated MAP kinase signaling pathway.


Figure 2: Effect of Deltap85 expression on G(i)-coupled receptor- and Gbeta-mediated MAP kinase (HA-ERK1) activation. COS-7 cells were cotransfected with plasmid DNA encoding p44 (0.1 µg/well) and either pRK5 alone (2.0 µg/well), Gbeta1 and G2 (1.0 µg each/well), or alpha(2)AR (0.2 µg/well) or pRK5 (2.0). Cells were also cotransfected with Deltap85 (2.0 µg/well) where indicated. Cells were stimulated with vehicle, LPA (10 µM), the alpha(2)AR agonist UK-14304 (10 µM), PMA (1.0 µM), or EGF (10 ng/ml) for 5 min, and MAP kinase activation was determined. The data are expressed as fold stimulation where basal MAP kinase activity is defined as 1.0. Values are mean ± S.E. from three separate experiments.



In PC12 cells, GTP-dependent association of Ras with the catalytic subunit of PI-3K has been described(23) , suggesting that activation of the p85/p110 PI-3K occurs subsequent to Ras activation. In contrast, a constitutively active mutant of PI-3K stimulates Ras-dependent Xenopus oocyte maturation and fos transcription (37) suggesting PI-3K activation precedes Ras activation in this system. To determine whether PI-3K activation in the G(i)-coupled receptor/Gbeta-mediated MAP kinase signaling pathway precedes or follows Ras activation, the effect of PI-3K inhibitors on G(i)-coupled receptor-mediated Ras activation was determined. As shown in Fig. 3, LPA-stimulated Ras activation is abolished by wortmannin and LY294002 pretreatment. In contrast, EGF-stimulated Ras activation is not significantly affected. The striking sensitivity of the LPA-stimulated signal to inhibition of PI-3K activity suggests a crucial role for PI-3K activity early in the G(i)-coupled receptor/Gbeta-mediated MAP kinase signaling pathway.


Figure 3: Effect of PI-3K inhibitors on LPA- and EGF-mediated Ras activation. COS-7 cells were preincubated for 15 min with wortmannin (1.0 µM), LY294002 (20 µM), or vehicle. Cells were then treated for 2 min with vehicle, LPA (10 µM), or EGF (10 ng/ml), and Ras activation was determined. Data are shown as GTP bound to Ras as a percent of the total guanyl nucleotides bound to Ras. Values represent the mean ± S.E. from three separate experiments.



Further evidence that PI-3K activation is an early event in the Gbeta-mediated MAP kinase signaling pathway is provided by the results in Fig. 4. The effect of PI-3K inhibition on MAP kinase activation provoked by overexpression of Sos, constitutively active Ras (T24Ras), and constitutively active MEK (MEK+) in COS-7 cells was assessed. Pretreatment with wortmannin or LY294002 (Fig. 4A) or overexpression of Deltap85 (data not shown) has no effect on the increase in MAP kinase activation stimulated by Sos, T24Ras, or MEK+ (Fig. 4A), suggesting PI-3K activity is upstream of these intermediates in the Gbeta-mediated MAP kinase activation pathway.


Figure 4: Effect of PI-3K inhibitors on MAP kinase (HA-ERK1) activation stimulated by intermediates of the Gbeta-mediated mitogenic signaling pathway. COS-7 (A) and CHO-K1 (B) cells were cotransfected with plasmid DNA encoding p44 (0.1 µg/well) and 1.0 µg/well of Sos, T24Ras, or MEK+ (A) and Gbeta1/G2, Sos, or Gbeta1/G2 and Sos (B). Cells were pretreated for 15 min with vehicle, wortmannin (1.0 µM), or LY294002 (20 µM), and MAP kinase activity was determined. The data are expressed as fold MAP kinase activity in which the basal MAP kinase activity is defined as 1.0. Values are the mean ± S.E. from at least three separate experiments.



In CHO-K1 cells, coexpression of Gbeta with Sos results in a synergistic increase in MAP kinase activation(19) . Expression of Gbeta or Sos alone stimulates a 2-3-fold and 5-fold increase, respectively, in MAP kinase activation (Fig. 4B). Coexpression of Gbeta and Sos results in a 15-20-fold increase in MAP kinase activation. As in COS-7 cells, Gbeta-mediated MAP kinase activation in CHO-K1 cells is abolished by wortmannin or LY294002 pretreatment, and Sos-stimulated MAP kinase activation is unaffected. The synergistic increase in MAP kinase activation produced by Gbeta and Sos coexpression is not observed in cells pretreated with wortmannin or LY294002 (Fig. 4B). Thus, the ability of Gbeta subunits to synergize with Sos is dependent on PI-3K activity, suggesting that PI-3K activity is required downstream of Gbeta, but upstream of Sos in the G(i)-mediated MAP kinase activation signaling pathway.

A role for PI-3K in mitogenic signaling has been suggested by previous studies showing that PI-3K can associate with activated RTKs and Src family kinases(38, 39, 40) . PI-3K association with the Grb2-Sos complex has been demonstrated following monocyte colony-stimulating factor stimulation of human peripheral blood monocytes (41) and increased PI-3K/Shc association in cells transformed by BCR/abl oncoprotein has been reported(42) . Thus, PI-3K is capable of interacting with many mitogenic signaling intermediates.

Several studies have suggested a role for PI-3K in GPCR-mediated signaling. Activation of neutrophils by formylated-Met-Leu-Phe involves pertussis toxin-sensitive increases in PI-3K activity and PIP(3) production(25, 26, 27, 28, 29, 43) . Increased PI-3K activity is observed in anti-phosphotyrosine immunoprecipitates following activation of G protein-mediated systems(27) . Wortmannin attenuates platelet-activating factor-stimulated MAP kinase activation in guinea pig neutrophils (24) and pertussis toxin-sensitive somatostatin receptor-stimulated MAP kinase activation in CHO-K1 cells(22) . The results of the present study demonstrate that PI-3K activity is required in the Gbeta-mediated MAP kinase signaling pathway and that the site of PI-3K activity in the pathway is upstream of Sos.

We have previously observed that Gbeta-mediated Shc phosphorylation is sensitive to tyrosine kinase inhibitors and wortmannin(20) . Wortmannin-sensitive Gbeta-stimulated PI-3K activity has been described in platelets and neutrophils(44, 45, 46) , and a Gbeta-sensitive PI-3K (designated p110 or PI-3K) has been cloned(47) . It is thus attractive to speculate that PI-3K activity may be required for recruitment and activation of the tyrosine kinase(s) responsible for mediating Ras and MAP kinase activation.

It has recently been reported that a product of PI-3K activity, phosphatidylinositol 3,4,5-trisphosphate (PIP(3)), is capable of binding with high affinity to the SH2 domains of proteins such as Src and the p85 subunit of PI-3K(48) . Further, PIP(3) can compete with tyrosine-phosphorylated proteins for binding to these sites. The PIP(3)/SH2 interaction may suggest a novel mechanism for regulating signaling pathways in PI-3K-dependent systems. PIP(3) may block phosphoprotein binding to SH2 domain-containing proteins or even supplant phosphoproteins bound to an SH2 domain. It is therefore possible that PIP(3) may serve as an intermediate in the Gbeta-mediated MAP kinase signaling pathway.

The ability of Deltap85 to inhibit Gbeta-mediated MAP kinase activation may indicate a requirement for the p85alpha-p110 complex in the pathway, possibly as part of a complex containing Shc and a Src family tyrosine kinase(49) . Alternatively, Deltap85 may inhibit the Gbeta signal by binding directly to PIP(3). Binding of Deltap85 to PIP(3) may disrupt PI-3K-dependent signaling by preventing PIP(3) from competing with phosphoproteins for binding to an SH2 domain. Therefore, it is possible that both p85-p110 PI-3K- and PI-3K-dependent signaling can be inhibited by expression of Deltap85. Further investigation is required to determine which PI-3K isotype is utilized in the Gbeta-mediated MAP kinase signaling pathway, the mechanism by which PI-3K activity provokes tyrosine kinase activation resulting in Shc phosphorylation and the identity of the tyrosine kinase utilized in this pathway.


FOOTNOTES

*
This work was supported in part by National Institutes of Health Grant HL 16037 (to R. J. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Present address: Schering Plough Research Institute, 2015 Galloping Hill Rd., Kenilworth, NJ 07033.

Recipient of a National Institutes of Health Clinical Investigator Development Award.

**
Recipient of a postdoctoral fellowship from the Alberta Heritage Foundation for Medical Research.

§§
To whom correspondence and requests for reprints should be addressed. Tel.: 919-684-2974; Fax: 919-684-8875.

(^1)
The abbreviations used are: RTK, receptor-tyrosine kinase; MAP, mitogen-activated protein; PI-3K, phosphatidylinositol 3-kinase; MEK, mitogen-activated protein kinase/Erk kinase; MEK+, a constitutively active mutant of MEK; IP, inositol phosphates; GPCR, G protein-coupled receptor; EGF, epidermal growth factor; Gbeta, the beta subunit of the G protein; MBP, myelin basic protein; DMEM, Dulbecco's modified Eagle's medium; LPA, lysophosphatidic acid; PMA, phorbol 12-myristate 13-acetate; FBS, fetal bovine serum; alpha(2)AR, alpha adrenergic receptor; T24Ras, a constitutively active mutant of Ras; Deltap85, a dominant negative mutant of the p85 subunit of PI-3K; PIP(3), phosphatidylinositol 3,4,5-trisphosphate; SH2 and SH3, Src homology domains.


ACKNOWLEDGEMENTS

We thank Drs. W. J. Koch and J. R. Raymond for helpful discussions and D. Addison and M. Holben for excellent secretarial assistance.


REFERENCES

  1. Blenis, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5889-5892 [Abstract]
  2. Alblas, J., van Corven, E. J., Hordijk, P. L., Milligan, G., and Moolenaar, W. H. (1993) J. Biol. Chem. 268, 22235-22238 [Abstract/Free Full Text]
  3. van Corven, E. J., Hordijk, P. L., Medema, R. H., Bos, J. L., and Moolenaar, W. H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1257-1261 [Abstract]
  4. Winitz, S., Gupta, S. K., Qian, N. X., Heasley, L. E., Nemenoff, R. A., and Johnson, G. L. (1994) J. Biol. Chem. 269, 1889-1895 [Abstract/Free Full Text]
  5. Marshall, C. J. (1995) Cell 80, 179-185 [Medline] [Order article via Infotrieve]
  6. Dhanasekaran, N., Heasley, L. E., and Johnson, G. L. (1995) Endocr. Rev. 16, 259-270 [Medline] [Order article via Infotrieve]
  7. Buday, L., and Downward, J. (1993) Cell 73, 611-620 [Medline] [Order article via Infotrieve]
  8. Ravichandran, K. S., Lorenz, U., Shoelson, S. E., and Burakoff, S. J. (1995) Mol. Cell. Biol. 15, 593-600 [Abstract]
  9. Sasaoka, T., Langlois, W. J., Leitner, J. W., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269, 32621-32625 [Abstract/Free Full Text]
  10. Aronheim, A., Engelberg, D., Li, N., al-Alawi, N., Schlessinger, J., and Karin, M. (1994) Cell 78, 949-961 [Medline] [Order article via Infotrieve]
  11. Leevers, S. J., Paterson, H. F., and Marshall, C. J. (1994) Nature 369, 411-414 [CrossRef][Medline] [Order article via Infotrieve]
  12. Howe, L. R., Leevers, S. J., Gomez, N., Nakielny, S., Cohen, P., and Marshall, C. J. (1992) Cell 71, 335-342 [Medline] [Order article via Infotrieve]
  13. de Vries-Smits, A. M., Burgering, B. M., Leevers, S. J., Marshall, C. J., and Bos, J. L. (1992) Nature 357, 602-604 [CrossRef][Medline] [Order article via Infotrieve]
  14. Koch, W. J., Hawes, B. E., Allen, L. F., and Lefkowitz, R. J. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12706-12710 [Abstract/Free Full Text]
  15. Faure, M., Voyno Yasenetskaya, T. A., and Bourne, H. R. (1994) J. Biol. Chem. 269, 7851-7854 [Abstract/Free Full Text]
  16. Crespo, P., Xu, N., Simonds, W. F., and Gutkind, J. S. (1994) Nature 369, 418-420 [CrossRef][Medline] [Order article via Infotrieve]
  17. Hawes, B. E., van Biesen, T., Koch, W. J., Luttrell, L. M., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 17148-17153 [Abstract/Free Full Text]
  18. van Biesen, T., Hawes, B. E., Raymond, J. R., Luttrell, L. M., and Lefkowitz, R. J. (1996) J. Biol. Chem. 271, 1266-1269 [Abstract/Free Full Text]
  19. van Biesen, T., Hawes, B. E., Luttrell, D. K., Krueger, K. M., Touhara, K., Porfiri, E, Sakaue, M., Luttrell, L. M., and Lefkowitz, R. J. (1995) Nature 376, 781-784 [CrossRef][Medline] [Order article via Infotrieve]
  20. Touhara, K., Hawes, B. E., van Biesen, T., and Lefkowitz, R. J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 9284-9287 [Abstract]
  21. Hordijk, P. L., Verlaan, I., van Corven, E. J., and Moolenaar, W. H. (1994) J. Biol. Chem. 269, 645-651 [Abstract/Free Full Text]
  22. Sakanaka, C., Ferby, I., Waga, I., Bito, H., and Shimizu, T. (1994) Biochem. Biophys. Res. Commun. 205, 18-23 [CrossRef][Medline] [Order article via Infotrieve]
  23. Rodriguez Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  24. Ferby, I. M., Waga, I., Sakanaka, C., Kume, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 30485-30488 [Abstract/Free Full Text]
  25. Stephens, L., Eguinoa, A., Corey, S., Jackson, T., and Hawkins, P. T. (1993) EMBO J. 12, 2265-2273 [Abstract]
  26. Stephens, L. R., Hughes, K. T., and Irvine, R. F. (1991) Nature 351, 33-39 [CrossRef][Medline] [Order article via Infotrieve]
  27. Stephens, L., Jackson, T., and Hawkins, P. T. (1993) J. Biol. Chem. 268, 17162-17172 [Abstract/Free Full Text]
  28. Thelen, M., Wymann, M. P., and Langen, H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4960-4964 [Abstract]
  29. Traynor-Kaplan, A. E., Harris, A. L., Thompson, B. L., Taylor, P., and Sklar, L. A. (1988) Nature 334, 353-356 [CrossRef][Medline] [Order article via Infotrieve]
  30. Ui, M., Okada, T., Hazeki, K., and Hazeki, O. (1995) Trends Biochem. Sci. 20, 303-307 [CrossRef][Medline] [Order article via Infotrieve]
  31. Kobilka, B. K., Matsui, H., Kobilka, T. S., Yang-Feng, T. L., Francke, U., Caron, M. G., and Regan, J. W. (1987) Science 238, 650-656 [Medline] [Order article via Infotrieve]
  32. Meloche, S., Pages, G., and Pouysségur, J. (1992) Mol. Biol. Cell 3, 63-71 [Abstract]
  33. Luttrell, L. M., van Biesen, T., Hawes, B. E., Koch, W. J., Touhara, K., and Lefkowitz, R. J. (1995) J. Biol. Chem. 270, 16495-16498 [Abstract/Free Full Text]
  34. Hawes, B. E., Luttrell, L. M., Exum, S. T., and Lefkowitz, R. J. (1994) J. Biol. Chem. 269, 15776-15785 [Abstract/Free Full Text]
  35. Gibbs, J. B., Marshall, M. S., Scolnick, E. M., Dixon, R. A., and Vogel, U. S. (1990) J. Biol. Chem. 265, 20437-20442 [Abstract/Free Full Text]
  36. Hara, K., Yonezawa, K., Sakaue, H., Ando, A., Kotani, K., Kitamura, T., Kitamura, Y., Ueda, H., Stephens, L., and Jackson, T. R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 7415-7419 [Abstract]
  37. Hu, Q., Klippel, A., Muslin, A. J., Fantl, W. J., and Williams, L. T. (1995) Science 268, 100-102 [Medline] [Order article via Infotrieve]
  38. Corey, S., Eguinoa, A., Puyana-Theall, K., Bolen, J. B., Cantley, L., Mollinedo, F., Jackson, T. R., Hawkins, P. T., and Stephens, L. R. (1993) EMBO J. 12, 2681-2690 [Abstract]
  39. Yamanashi, Y., Fukui, Y., Wongsasant, B., Kinoshita, Y., Ichimori, Y., and Yamamoto, T. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1118-1122 [Abstract]
  40. Pleiman, C. M., Hertz, W. M., and Cambier, J. C. (1994) Science 263, 1609-1612 [Medline] [Order article via Infotrieve]
  41. Saleem, A., Kharbanda, S., Yuan, Z. M., and Kufe, D. (1995) J. Biol. Chem. 270, 10380-10383 [Abstract/Free Full Text]
  42. Harrison-Findik, D., Susa, M., and Varticovski, L. (1995) Oncogene 10, 1385-1391 [Medline] [Order article via Infotrieve]
  43. Traynor-Kaplan, A. E., Thompson, B. L., Harris, A. L., Taylor, P., Omann, G. M., and Sklar, L. A. (1989) J. Biol. Chem. 264, 15668-15673 [Abstract/Free Full Text]
  44. Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C., and Hawkins, P. T. (1994) Cell 77, 83-93 [Medline] [Order article via Infotrieve]
  45. Thomason, P. A., James, S. R., Casey, P. J., and Downes, C. P. (1994) J. Biol. Chem. 269, 16525-16528 [Abstract/Free Full Text]
  46. Zhang, J., Benovic, J. L., Sugai, M., Wetzker, R., and Gout, I. (1995) J. Biol. Chem. 270, 6589-6594 [Abstract/Free Full Text]
  47. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebroeck, B., Dhand, R., Nurnberg, B., Gierschik, P., Seedorf, K., Hsuan, J. J., Waterfield, M. D., and Wetzker, R. (1995) Science 269, 690-693 [Medline] [Order article via Infotrieve]
  48. Rameh, L. E., Chen, C.-S., and Cantley, L. C. (1995) Cell 83, 821-830 [Medline] [Order article via Infotrieve]
  49. Ptasznik, A., Traynor-Kaplan, A., and Bokoch, G. M. (1995) J. Biol. Chem. 270, 19969-19973 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.